Hepatitis C is known to be a main health concern for many Egyptians. On the occasion of World Hepatitis Day and in the presence of Dr. Ammal Mokhtar _Regional Director of the World Hepatitis Alliance in the Eastern Mediterranean Region, a press conference was held by Al-Borg Laboratories in collaboration with Roche Diagnostics where Chairman of Al-Borg Laboratories, Proff. Dr. Fatma Nasrat _Professor of Clinical Immunology at the Cancer Institute and Head of Immunology unit of Al Borg Laboratories, has announced that over 450,000 Egyptians have undergone Hepatitis C screening tests across the labs’ branches throughout 2016-2017.
Commenting on the findings, Prof. Dr. Fatma Nasrat said: “Early detection is the basis for successful Hepatitis treatment. There is a need to spread awareness outside the major cities, to encourage more individuals to undergo early detection tests. This is clear from the data showing that among the people who have undergone testing for Hepatitis C 37% were from the Delta region, while Cairo represented 35%, 18% from Upper Egypt and only 10% from Alexandria.”
Professor Ammal Mokhtar, who is also the Head of Community Medicine Research at the National Research Center and Director of the Epidemiology Unit at the Egyptian Liver Hospital in Dakahlia, said that despite the reduction of Virus C from 14.6% in 2008 to 7.5% 2015 for age groups 15-60 years, it is still considered one of the highest rates in the world, especially in rural areas. She also added that liver disease is the leading cause of death in Egypt in proportion to people with chronic liver disease which represent 2-7% of the community. It is important to point out that screening is the only way to detect Hepatitis B and C and that the chances of success for the treatment of virus C depend on early and periodical testing, in which case treatment should happen immediately after the discovery of the antibodies.
Harald Wolf – General Manager Roche Diagnostics Middle East, commented: “Innovation is at the very heart of what we do at Roche Diagnostics. We are proud to introduce the latest technologies to laboratories like Al Borg; deeply committed to elevating patient care in Egypt through instilling the highest standards of quality in every aspect possible.”
HCV is one of the main public health challenges affecting Egyptians, with a national prevalence of 4.4% among people aged 1–59 years. When serious diseases like this heavily prevalent in the country, the need for reliable and accurate testing to increase the number of diagnosed cases is greater than ever.i Wth the aid of the latest technologies, the two healthcare giants (Al-Borg & Roche) can help improve patient’s lives.